Daiichi Sankyo files for Japanese approval of antihypertensive combination drug
CS-866AZ is a combination drug of the long-acting calcium channel blocker azelnidipine (Calblock jointly researched and developed by Daiichi Sankyo and its partner Ube Industries) and the high
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.